WO1999003486A1 - Antacid and papain combination - Google Patents

Antacid and papain combination Download PDF

Info

Publication number
WO1999003486A1
WO1999003486A1 PCT/US1998/014233 US9814233W WO9903486A1 WO 1999003486 A1 WO1999003486 A1 WO 1999003486A1 US 9814233 W US9814233 W US 9814233W WO 9903486 A1 WO9903486 A1 WO 9903486A1
Authority
WO
WIPO (PCT)
Prior art keywords
dose
composition
amount
compositions
composition according
Prior art date
Application number
PCT/US1998/014233
Other languages
French (fr)
Inventor
Constantine Georgiades
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Priority to JP50751899A priority Critical patent/JP2002509539A/en
Priority to BR9809419-0A priority patent/BR9809419A/en
Priority to EP98933290A priority patent/EP1001796A1/en
Priority to AU82968/98A priority patent/AU8296898A/en
Priority to CA002286357A priority patent/CA2286357A1/en
Publication of WO1999003486A1 publication Critical patent/WO1999003486A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22002—Papain (3.4.22.2)

Definitions

  • This invention relates to a composition for treating the symptoms of excess gastric acid secretion, such as heartburn, sour stomach, acid indigestion and upset stomach.
  • the composition of this invention is a combination of: 1) one or more compositions that reduce gastric acidity; and, 2) papaya extract.
  • compositions that provide relief from gastric hyperacidity. These compositions include, but are not limited to, compositions that reduce intragastric hydrogen ion concentration by chemical neutralization such as calcium carbonate (e.g. Turns®), magnesium hydroxide (e.g. Mylanta®), a combination of calcium carbonate and magnesium hydroxide (e.g.
  • H 2 receptor antagonists such as ranitidine (e.g. Zantac®), cimetidine (e.g. Tagemet®), and the like; proton-pump inhibitors such as omeprazole; bismuth compounds; prostaglandins; sucralfate; and, dopamine antagonists such as cisapride.
  • compositions are effective, some are not long lasting, while others have a delayed onset of action. More specifically, compositions such as Turns®, Mylanta®, and Rolaids® are not long lasting, whereas H 2 receptor antagonists, proton-pump inhibitors, and others do not have a rapid onset of action (i.e. less than one minute). A composition capable of overcoming these disadvantages is therefore desired.
  • papaya a fruit of the melon tree Carica papaya Linn has been known for centuries. Studies have shown the juice from the fruit, also referred to as latex, contains proteolytic enzymes, which have been identified as papain, chymopapain and papaya proteinase III. Papain is the most characterized among the three. Its approximate molecular weight is 21,000, and it contains 18 different amino acids in a sequence of 211 amino acids.
  • the present invention is directed to a composition comprising: 1) one or more compositions that reduce stomach acidity; and, 2) a composition extracted from papaya, preferably comprising one or more proteolytic enzymes, including but not limited to, papain, chymopapain and papaya proteinase III.
  • This composition can be used to provide improved, convenient relief from gastric distress resulting from excess gastric acid secretion.
  • the present invention is further directed to a method of preparing a composition comprising: 1) one or more compositions that reduce stomach acidity; and, 2) a composition extracted from papaya, preferably comprising one or more proteolytic enzymes, including but not limited to, papain, chymopapain and papaya proteinase III.
  • the present invention is further directed to a method of using a composition
  • a composition comprising: 1) one or more compositions that reduce stomach acidity; and, 2) a composition extracted from papaya, preferably comprising one or more proteolytic enzymes, including but not limited to, papain, chymopapain and papaya proteinase
  • the present invention is directed to a composition for relieving stomach distress comprising: 1) one or more compositions that reduce gastric acidity; and, 2) a composition extracted from papaya, preferably comprising one or more proteolytic enzymes, including but not limited to, papain, chymopapain and papaya proteinase III.
  • This composition can be used to provide improved, convenient relief from gastric distress resulting from excess gastric acid secretion.
  • This invention is further directed to a method of preparing and a method of using such a composition for providing improved relief of gastric distress.
  • the amounts of the ingredients that can be used in this composition are generally the ordinary dosages required to obtain the desired result.
  • the amount of the first component that reduces gastric acidity is present in an amount of from about 10 mg/dose to about 1500 mg/dose and the amount of the papaya extract is present in an amount of from about 50 mg/dose to about 3000 mg/dose.
  • compositions that reduce gastric acidity may be any of the following: compositions that reduce intragastric hydrogen ion concentration by chemical neturalization; H 2 receptor antagonists; proton-pump inhibitors: bismuth compounds; prostaglandins; sucralfate; and dopamine antagonists. These compositions are herewith defined as "antacids.”
  • the composition of this invention may comprise one or more than one of these antacids.
  • improved relief from gastric distress can be either relief that has a longer duration of action and/or a faster onset of action than would occur from ingesting the antacid component alone of this inventive composition alone.
  • compositions that reduce gastric acidity by chemical neutralization are: aluminum-containing active ingredients; bicarbonate-containing active ingredients; bismuth-containing active ingredients; calcium-containing active ingredients; citrate-containing active ingredients; glycine; magnesium-containing active ingredients; dried milk solids; phosphate-containing active ingredients; potassium-containing active ingredients; sodium-containing active ingredients; silicates and tartrate-containing active ingredients; and other compositions recognized by the U.S. Food and Drug Administration (FDA) as useful for the relief of heartburn, sour stomach, or acid indigestion and upset stomach.
  • FDA U.S. Food and Drug Administration
  • calcium carbonate and magnesium hydroxide are the preferred chemical neutralizing compositions. Calcium carbonate is the most preferred.
  • Receptor antagonists reduce gastric acid secretion by blocking histamine receptors in the stomach lining. Histamine stimulates gastric secretion via H 2 receptors.
  • H 2 receptor antagonists are: ranitidine, cimetidine, famotidine, mifentidine, roxatidine, and mizatidine.
  • the amount of H 2 receptor antagonist that can be used in this invention is from about 10 mg/dose to about 800 mg/dose.
  • ranitidine is the preferred H 2 receptor antagonist.
  • the amount of ranitidine that can be used in this invention is from about 75 mg/dose to about 300 mg/dose.
  • Proton pump inhibitors block the membrane pump on the parietal cells in the stomach that are responsible for exchanging potassium from the gastric lumen with hydrogen ions. Blocking this membrane pump inhibits gastric acid secretion.
  • a nonlimiting example of a proton pump inhibitor is omeprazole.
  • Bismuth compounds act in a number of ways to reduce gastrointestinal distress.
  • a nonlimiting example of a bismuth compound is bismuth subcitrate, also known as tripotassium dicitrato bismuthate.
  • Prostaglandins are lipid hormones found in virtually all tissues. It is believed that one effect of prostaglandins in the stomach is reduction of acid secretion. They may also enhance mucosal resistance to stomach irritation.
  • Nonlimiting examples of prostaglandins are PGEi of which misoprostol is an analogue: PGE 2 , of which arabaprostil and enprostil are analogues; PGIi, and methyl analogs of prostaglandins of the E series.
  • Sucralfate is a complex salt of polyaluminium hydroxide with a sulphated saccharide skeleton which has been proven clinically to be effective in the treatment of gastric and duodenal ulceration. It is a weak buffer with a pK of approximately 4.5.
  • Dopamine antagonists are believed to relieve gastric distress by increasing gastrointestinal motility and decreasing transit time.
  • Nonlimiting examples of dopamine antagonists are metoclopramide, domperidone. and cisapride.
  • the amount of the foregoing compositions that reduce gastric acidity that are used in this invention may vary depending upon the therapeutic dosage recommended or permitted for the particular agent. In general, the amount of these compositions is the ordinary dosage required to obtain the desired result. In one embodiment of this invention the amount of compositions that reduce gastric acidity by chemical neutralization are present in an amount of from about 250 mg to about 1450 mg/dose.
  • the dosage form may be a tablet, caplet, capsule, powder, troche, lozenge, elixir, and the like. Such dosages are known to the skilled practitioner in the medical arts. Preferred dosage forms are tablets and caplets.
  • magnesium hydroxide is in an amount of from about 50 to about 800 mg/dose; preferably in an amount of from about 80 mg to about 600 mg/dose; and most preferably from about 100 mg to about 400 mg/dose.
  • calcium carbonate is in an amount of about 200 to about 1250 mg/dose; preferably from about 400 mg to about 1000 mg/dose; and most preferably from about 500 mg to about 800 mg/dose.
  • Another preferred embodiment of this invention contains both magnesium hydroxide and calcium carbonate in an amount of magnesium hydroxide of from about 50 mg to about 400 mg/dose and calcium carbonate in an amount of from about 200 mg to about 1250 mg/dose; preferably an amount of magnesium hydroxide of from about 80 mg to about 300 mg/dose and calcium carbonate in an amount of from about 400 mg to about 1000 mg/dose; and most preferably an amount of magnesium hydroxide of from about 100 mg to about 260 mg/dose and calcium carbonate in an amount of from about about 500 mg to about 800 mg/dose.
  • the present invention further includes a composition extracted from the juice, pulp, or other parts of papaya.
  • the composition extracted from papaya is defined as papaya extract.
  • One embodiment of this invention comprises one or more proteolytic enzymes from papaya extract.
  • proteolytic enzymes are papain, chymopapain, and papaya proteinase III.
  • the preferred enzyme is papain.
  • the papaya extract of this invention may be in a variety of forms. Nonlimiting examples of these forms are: the dried powdered latex of papaya; freeze dried papaya powder; papaya juice powder; crystalline papain; and crystalline chymopapain.
  • the preferred forms are freeze dried papaya powder and papaya juice powder.
  • the amount of papaya extract in each dose of the composition of this invention is from about 50 mg to about 3000 mg.
  • the preferred amount is from about 100 mg to about 1000 mg.
  • the most preferred amount is from about 200 mg to about 800 mg.
  • Another embodiment of this inventive composition contains one or more proteolytic enzymes found in papaya extract, including but not limited to papain, chymopapain, and papaya protease III. These enzymes may be relatively pure (i.e. of pharmaceutical grade), but preparations of less pure enzymes are also acceptable.
  • the amount of the one or more proteolytic enzymes per dose in this embodiment is from about 0.5 to about 600 mg; preferably from about 1.5 mg to about 300 mg; and most preferably from about 2.5 mg to about 200 mg.
  • composition of this invention may also contain other ingredients and excipients known to one skilled in the art.
  • additional ingredients include excipients, binders, coloring, flavoring, sugars, starches and the like.
  • the composition of this invention may be used in many distinct physical forms well known in the pharmaceutical art to provide an initial dosage of the inventive composition and/or a further time-release form of the inventive composition.
  • such physical forms include tablets, caplets, capsules, powders, troches, lozenges, elixirs, and the like.
  • composition of this invention is made by admixing one or more antacids of this invention with dried papaya extract as well as other dry ingredients such as excipients, binders, starches, sugars and the like. These ingredients are then blended thoroughly and prepared as powders, tablets, caplets, capsules, and the like according to skills known in the art.
  • Another method of preparing the composition of this invention comprises thoroughly blending the dry ingredients then further combining them with liquid papaya extract and blending, then further combining with water, corn syrup, and the like in order to prepare a liquid form of the invention. By using additional methods known to one skilled in the art, this liquid form of the invention can then be prepared to form a lozenge, troche, and the like.
  • This invention extends to methods for using the inventive composition.
  • these methods employ ingesting the inventive composition in an amount and frequency sufficient to provide improved treatment of symptoms caused by excess gastric acid secretion.
  • compositions according to this invention are provided to illustrate, but not limit, the claimed invention.
  • the sugar, calcium carbonates, magnesium hydroxide, pregelatinized starch and polyethylene glycol were previously combined with water, and blended to from a uniform, dry, powdered composition. These ingredients were then blended with the papaya juice powder, flavor, starch 1500, and silica for twenty minutes using a half- quart P-K blender. The magnesium stearate is then added to this mixture and blended for five minutes.
  • the blended composition is then compressed into hard, pleasant tasting tablets using conventional technology.
  • the amount of papaya extract contained in each dose can range from about 50 mg to 3000 mg with about 100 mg to about 1000 mg preferred.
  • the particular form of papaya extract used is not believed to be critical in the present invention, however, the purer the form used the less the amount of extract needed for each dose.

Abstract

A composition for relieving stomach distress is disclosed. The composition comprises a combination of one or more compositions that reduce gastric acidity and a composition extracted from papaya, preferably comprising one or more proteolytic enzymes. Also disclosed are methods of making and methods of using such compositions.

Description

TITLE
ANTACID AND PAPAIN COMBINATION
Field of the Invention
This invention relates to a composition for treating the symptoms of excess gastric acid secretion, such as heartburn, sour stomach, acid indigestion and upset stomach. The composition of this invention is a combination of: 1) one or more compositions that reduce gastric acidity; and, 2) papaya extract.
Background Of The Invention
It is well known that excess production of stomach acid can cause symptoms of gastric distress, heartburn, dyspepsia, and the like. For the vast majority of people, symptoms of gastric hyperacidity occur after certain foods have been consumed. Spicy foods, pickled foods, peppers, tomatoes and citrus fruits are among those foods that frequently cause hyperacidity. There are a number of compositions that provide relief from gastric hyperacidity. These compositions include, but are not limited to, compositions that reduce intragastric hydrogen ion concentration by chemical neutralization such as calcium carbonate (e.g. Turns®), magnesium hydroxide (e.g. Mylanta®), a combination of calcium carbonate and magnesium hydroxide (e.g. Rolaids®) and the like; H2 receptor antagonists such as ranitidine (e.g. Zantac®), cimetidine (e.g. Tagemet®), and the like; proton-pump inhibitors such as omeprazole; bismuth compounds; prostaglandins; sucralfate; and, dopamine antagonists such as cisapride. Each of these classes of compositions have different mechanisms of action, yet all have been shown to be effective in reducing or eliminating symptoms of gastric hyperacidity.
While the foregoing compositions are effective, some are not long lasting, while others have a delayed onset of action. More specifically, compositions such as Turns®, Mylanta®, and Rolaids® are not long lasting, whereas H2 receptor antagonists, proton-pump inhibitors, and others do not have a rapid onset of action (i.e. less than one minute). A composition capable of overcoming these disadvantages is therefore desired.
The digestive action of papaya, a fruit of the melon tree Carica papaya Linn has been known for centuries. Studies have shown the juice from the fruit, also referred to as latex, contains proteolytic enzymes, which have been identified as papain, chymopapain and papaya proteinase III. Papain is the most characterized among the three. Its approximate molecular weight is 21,000, and it contains 18 different amino acids in a sequence of 211 amino acids.
While it is not certain exactly what compounds in papaya reduce gastric acidity, studies in rats have shown that feeding the latex of unripe papaya fruit significantly reduced acid secretion induced by methocholine. Feeding of crystalline papain in doses of 3.2 mg/kg reduced reduced gastric acid secretion. Reduction of gastric acid secretion was observed as early as 2 hours after administration and lasted as long as 48 hours in the rat. Cho, et al, Proc. Natl. Sci. Counc. ROC(B), 8(2), 177-181 (1984).
Combinations of pure digestive enzymes, such as proteases, in a stable aqueous colloidal suspension with aluminum hydroxide are disclosed in U.S. Pat. No. 3,329,564. The proteases or other digestive enzymes are added to the aluminum hydroxide antacid in small quantities to provide the digestive benefits of enzymatic action to an antacid preparation. However, these compositions are inconvenient to use because they are suspensions.
It is therefore an object of this invention to provide a composition that is capable of providing improved relief from the effects of excess gastric acid secretion. It is also desired to provide such a composition in a form that is convenient to carry or transport.
SUMMARY OF THE INVENTION
The present invention is directed to a composition comprising: 1) one or more compositions that reduce stomach acidity; and, 2) a composition extracted from papaya, preferably comprising one or more proteolytic enzymes, including but not limited to, papain, chymopapain and papaya proteinase III. This composition can be used to provide improved, convenient relief from gastric distress resulting from excess gastric acid secretion. The present invention is further directed to a method of preparing a composition comprising: 1) one or more compositions that reduce stomach acidity; and, 2) a composition extracted from papaya, preferably comprising one or more proteolytic enzymes, including but not limited to, papain, chymopapain and papaya proteinase III.
The present invention is further directed to a method of using a composition comprising: 1) one or more compositions that reduce stomach acidity; and, 2) a composition extracted from papaya, preferably comprising one or more proteolytic enzymes, including but not limited to, papain, chymopapain and papaya proteinase
III.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to a composition for relieving stomach distress comprising: 1) one or more compositions that reduce gastric acidity; and, 2) a composition extracted from papaya, preferably comprising one or more proteolytic enzymes, including but not limited to, papain, chymopapain and papaya proteinase III. This composition can be used to provide improved, convenient relief from gastric distress resulting from excess gastric acid secretion. This invention is further directed to a method of preparing and a method of using such a composition for providing improved relief of gastric distress.
The amounts of the ingredients that can be used in this composition are generally the ordinary dosages required to obtain the desired result. In one embodiment the amount of the first component that reduces gastric acidity is present in an amount of from about 10 mg/dose to about 1500 mg/dose and the amount of the papaya extract is present in an amount of from about 50 mg/dose to about 3000 mg/dose.
In accordance with this invention compositions that reduce gastric acidity may be any of the following: compositions that reduce intragastric hydrogen ion concentration by chemical neturalization; H2 receptor antagonists; proton-pump inhibitors: bismuth compounds; prostaglandins; sucralfate; and dopamine antagonists. These compositions are herewith defined as "antacids." The composition of this invention may comprise one or more than one of these antacids.
In accordance with this invention improved relief from gastric distress can be either relief that has a longer duration of action and/or a faster onset of action than would occur from ingesting the antacid component alone of this inventive composition alone.
Nonlimiting examples of compositions that reduce gastric acidity by chemical neutralization are: aluminum-containing active ingredients; bicarbonate-containing active ingredients; bismuth-containing active ingredients; calcium-containing active ingredients; citrate-containing active ingredients; glycine; magnesium-containing active ingredients; dried milk solids; phosphate-containing active ingredients; potassium-containing active ingredients; sodium-containing active ingredients; silicates and tartrate-containing active ingredients; and other compositions recognized by the U.S. Food and Drug Administration (FDA) as useful for the relief of heartburn, sour stomach, or acid indigestion and upset stomach. These compositions are listed in 21 C.F.R. § 331, which is hereby incorporated by reference in its entirety.
In this invention calcium carbonate and magnesium hydroxide are the preferred chemical neutralizing compositions. Calcium carbonate is the most preferred.
Receptor antagonists reduce gastric acid secretion by blocking histamine receptors in the stomach lining. Histamine stimulates gastric secretion via H2 receptors. Nonlimiting examples of H2 receptor antagonists are: ranitidine, cimetidine, famotidine, mifentidine, roxatidine, and mizatidine. The amount of H2 receptor antagonist that can be used in this invention is from about 10 mg/dose to about 800 mg/dose. In this invention ranitidine is the preferred H2 receptor antagonist. The amount of ranitidine that can be used in this invention is from about 75 mg/dose to about 300 mg/dose.
Proton pump inhibitors block the membrane pump on the parietal cells in the stomach that are responsible for exchanging potassium from the gastric lumen with hydrogen ions. Blocking this membrane pump inhibits gastric acid secretion. A nonlimiting example of a proton pump inhibitor is omeprazole.
Bismuth compounds act in a number of ways to reduce gastrointestinal distress. A nonlimiting example of a bismuth compound is bismuth subcitrate, also known as tripotassium dicitrato bismuthate.
Prostaglandins are lipid hormones found in virtually all tissues. It is believed that one effect of prostaglandins in the stomach is reduction of acid secretion. They may also enhance mucosal resistance to stomach irritation. Nonlimiting examples of prostaglandins are PGEi of which misoprostol is an analogue: PGE2, of which arabaprostil and enprostil are analogues; PGIi, and methyl analogs of prostaglandins of the E series.
Sucralfate is a complex salt of polyaluminium hydroxide with a sulphated saccharide skeleton which has been proven clinically to be effective in the treatment of gastric and duodenal ulceration. It is a weak buffer with a pK of approximately 4.5.
Dopamine antagonists are believed to relieve gastric distress by increasing gastrointestinal motility and decreasing transit time. Nonlimiting examples of dopamine antagonists are metoclopramide, domperidone. and cisapride.
The amount of the foregoing compositions that reduce gastric acidity that are used in this invention may vary depending upon the therapeutic dosage recommended or permitted for the particular agent. In general, the amount of these compositions is the ordinary dosage required to obtain the desired result. In one embodiment of this invention the amount of compositions that reduce gastric acidity by chemical neutralization are present in an amount of from about 250 mg to about 1450 mg/dose. The dosage form may be a tablet, caplet, capsule, powder, troche, lozenge, elixir, and the like. Such dosages are known to the skilled practitioner in the medical arts. Preferred dosage forms are tablets and caplets.
In a preferred embodiment magnesium hydroxide is in an amount of from about 50 to about 800 mg/dose; preferably in an amount of from about 80 mg to about 600 mg/dose; and most preferably from about 100 mg to about 400 mg/dose.
In another preferred embodiment calcium carbonate is in an amount of about 200 to about 1250 mg/dose; preferably from about 400 mg to about 1000 mg/dose; and most preferably from about 500 mg to about 800 mg/dose. Another preferred embodiment of this invention contains both magnesium hydroxide and calcium carbonate in an amount of magnesium hydroxide of from about 50 mg to about 400 mg/dose and calcium carbonate in an amount of from about 200 mg to about 1250 mg/dose; preferably an amount of magnesium hydroxide of from about 80 mg to about 300 mg/dose and calcium carbonate in an amount of from about 400 mg to about 1000 mg/dose; and most preferably an amount of magnesium hydroxide of from about 100 mg to about 260 mg/dose and calcium carbonate in an amount of from about about 500 mg to about 800 mg/dose.
The present invention further includes a composition extracted from the juice, pulp, or other parts of papaya. In this invention the composition extracted from papaya is defined as papaya extract. One embodiment of this invention comprises one or more proteolytic enzymes from papaya extract. Nonlimiting examples of proteolytic enzymes are papain, chymopapain, and papaya proteinase III. The preferred enzyme is papain. The papaya extract of this invention may be in a variety of forms. Nonlimiting examples of these forms are: the dried powdered latex of papaya; freeze dried papaya powder; papaya juice powder; crystalline papain; and crystalline chymopapain. The preferred forms are freeze dried papaya powder and papaya juice powder.
In one embodiment of this invention the amount of papaya extract in each dose of the composition of this invention is from about 50 mg to about 3000 mg. The preferred amount is from about 100 mg to about 1000 mg. The most preferred amount is from about 200 mg to about 800 mg. Another embodiment of this inventive composition contains one or more proteolytic enzymes found in papaya extract, including but not limited to papain, chymopapain, and papaya protease III. These enzymes may be relatively pure (i.e. of pharmaceutical grade), but preparations of less pure enzymes are also acceptable.
The amount of the one or more proteolytic enzymes per dose in this embodiment is from about 0.5 to about 600 mg; preferably from about 1.5 mg to about 300 mg; and most preferably from about 2.5 mg to about 200 mg.
The composition of this invention may also contain other ingredients and excipients known to one skilled in the art. Nonlimiting examples of these additional ingredients include excipients, binders, coloring, flavoring, sugars, starches and the like. The composition of this invention may be used in many distinct physical forms well known in the pharmaceutical art to provide an initial dosage of the inventive composition and/or a further time-release form of the inventive composition.
Without being limited thereto, such physical forms include tablets, caplets, capsules, powders, troches, lozenges, elixirs, and the like.
This invention extends to methods of making the inventive composition. In general the composition of this invention is made by admixing one or more antacids of this invention with dried papaya extract as well as other dry ingredients such as excipients, binders, starches, sugars and the like. These ingredients are then blended thoroughly and prepared as powders, tablets, caplets, capsules, and the like according to skills known in the art. Another method of preparing the composition of this invention comprises thoroughly blending the dry ingredients then further combining them with liquid papaya extract and blending, then further combining with water, corn syrup, and the like in order to prepare a liquid form of the invention. By using additional methods known to one skilled in the art, this liquid form of the invention can then be prepared to form a lozenge, troche, and the like.
This invention extends to methods for using the inventive composition. In general these methods employ ingesting the inventive composition in an amount and frequency sufficient to provide improved treatment of symptoms caused by excess gastric acid secretion.
Examples of compositions according to this invention are provided to illustrate, but not limit, the claimed invention.
Example 1
Sugar, Confectioners 6X (with starch) 35.54 grams
Calcium Carbonate Heavy USP 18.54 grams
Calcium Carbonate 9.13 grams
Magnesium Hydroxide 5.53 grams
Starch, Pregelatinized, NF .77 grams
Polyethylene Glycol 800 (Powdered) .70 grams
Papaya Juice Powder 25.00 grams
Flavor 0.60 gram
Starch 1500 3.376 grams
Silica, Amorphous Fumed 0.30 grams
Magnesium Stearate 0.50 grams The papaya juice powder was obtained from Island Organics, Inc., located at 500 Metuchen Rd., South Plainfield, New Jersey 07080.
The above ingredients were formed into fifty tablets following the procedure below:
The sugar, calcium carbonates, magnesium hydroxide, pregelatinized starch and polyethylene glycol were previously combined with water, and blended to from a uniform, dry, powdered composition. These ingredients were then blended with the papaya juice powder, flavor, starch 1500, and silica for twenty minutes using a half- quart P-K blender. The magnesium stearate is then added to this mixture and blended for five minutes.
The blended composition is then compressed into hard, pleasant tasting tablets using conventional technology.
Example 2
Sugar, Confectioners 6X (with starch) 21.32 gram
Calcium Carbonate Heavy USP 11.12 gram
Calcium Carbonate 5.48 grams
Magnesium Hydroxide 3.32 grams
Starch, Pregelatinized, NF .46 grams
Polyethylene Glycol 800 (Powdered) .42 grams
Freeze dried papaya powder 30.00 grams
Flavor 0.45 grams
Starch 1500 1.816 grams
Silica, Amorphous Fumed 0.225 grams
Magnesium Stearate 0.375 grams The freeze-dried papaya powder is available from Freeze Dry Product, USA located at 68 Leveioni Court, Suite 100, Navato, California. Thirty tablets were made using the same method described in Example 1. The tablet tastes good, but the blended ingredients showed less than ideal flowability.
The amount of papaya extract contained in each dose (or tablet) can range from about 50 mg to 3000 mg with about 100 mg to about 1000 mg preferred. The particular form of papaya extract used is not believed to be critical in the present invention, however, the purer the form used the less the amount of extract needed for each dose.

Claims

WE CLAIM:
1. A composition for relieving stomach distress comprising: 1) one or more compositions that reduce gastric acidity; and, 2) papaya extract.
2. The composition according to claim 1 wherein said compositions that reduce gastric acidity are selected from the group consisting of: compositions that reduce intragastric hydrogen ion concentration by chemical neutralization; H2 receptor antagonists; proton-pump inhibitors; bismuth compounds; prostaglandins; sucralfate; and dopamine antagonists.
3. The composition according to claim 2 wherein said composition that reduces gastric acidity is a composition that reduces intragastric hydrogen ion concentration by chemical neutralization.
4. The composition according to claim 3 wherein said composition that reduces intragastric hydrogen ion concentration by chemical neutralization is selected from the group consisting of calcium carbonate, magnesium hydroxide, and combinations therein.
5. The composition according to claim 4 wherein said composition that reduces intragastric hydrogen ion concentration by chemical neutralization is calcium carbonate and magnesium hydroxide.
6. The composition according to claim 5 wherein said magnesium hydroxide is in an amount of from about 50 mg/dose to about 400 mg/dose and said calcium carbonate is in an amount of from about 200 mg/dose to about 1250 mg/dose.
7. The composition according to claim 6 wherein said magnesium hydroxide is an amount of from about 80 mg/dose to about 300 mg/dose and said calcium carbonate is in an amount of from about 400 mg/dose to about 1000 mg/dose.
8. The composition according to claim 7 wherein said magnesium hydroxide is an amount of from about 100 mg/dose to about 260 mg/dose and said calcium carbonate is in an amount of from about 500 mg/dose to about 800 mg/dose.
9. The composition according to claim 2 wherein said composition that reduces gastric acidity is an H2 receptor antagonist and wherein said H2 receptor antagonist is in an amount of from about 10 mg/dose to about 800 mg/dose.
10. The composition according to claim 9 wherein said H2 receptor antagonist is ranitidine and wherein said ranitidine is in an amount of from about 75 mg/dose to about 300 mg/dose.
11. The composition according to claim 1 wherein said papaya extract is present in an amount of from about 50 mg to about 3000 mg/dose.
12. The composition according to claim 1 wherein said papaya extract consists of one or more proteolytic enzymes.
13. The composition according to claim 12 wherein said proteolytic enzymes are selected from the group consisting of papain, chymopapain, and papaya proteinase III.
14. The composition according to claim 13 wherein said proteolytic enzyme is papain.
15. The composition of claim 14 wherein said one or more proteolytic enzymes are present in an amount of from about 0.5 mg/dose to about 600 mg/dose.
16. The composition of claim 15 wherein said one or more proteolytic enzymes are present in an amount of from about 1.5 mg/dose to about 300 mg/dose.
17. The composition of claim 16 wherein said one more proteolytic enzymes are present in an amount of from about 2.5 mg/dose to about 200 mg/dose.
18. The composition according to claim 1 wherein said one or more compositions that reduce gastric acidity are present in an amount of from about 250 mg to about 1450 mg per tablet; and said papaya extract is present in an amount of from about 50 mg/dose to about 3000 mg/dose.
19. A method for preparing a composition for relieving stomach distress comprising one or more compositions that reduce gastric acidity; and, a composition extracted from papaya comprising the steps of: 1) admixing one or more compositions that reduce gastric acidity that are in dry form, dried papaya extract, and other dry ingredients selected from the group consisting of excipients, binders, starches, and sugars; and, 2) thoroughly blending the ingredients of step 1; and, 3) preparing the ingredients of step 2 as a powder.
20. The method of claim 19 further comprising the step of compressing said powder to form a tablet or caplet.
21. A method for preparing a composition for relieving stomach distress comprising one or more compositions that reduce gastric acidity; and, a composition extracted from papaya comprising the steps of: 1) admixing one or more compositions that reduce gastric acidity that are in dry form with other dry ingredients selected from the group consisting of excipients, binders, starches, and sugars; 2) further combining the ingredients of step 1) with liquid papaya extract and blending; and, 3) then further combining the ingredients of step 2 with water and corn syrup.
22. A method of using a composition for relieving stomach distress comprising: 1) one or more compositions that reduce gastric acidity; and, 2) a composition extracted from papaya comprising the step of ingesting said composition in an amount and frequency sufficient to provide relief of said stomach distress.
PCT/US1998/014233 1997-07-15 1998-07-08 Antacid and papain combination WO1999003486A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP50751899A JP2002509539A (en) 1997-07-15 1998-07-08 Combination of antacid and papain
BR9809419-0A BR9809419A (en) 1997-07-15 1998-07-08 Combination of antacid and papain
EP98933290A EP1001796A1 (en) 1997-07-15 1998-07-08 Antacid and papain combination
AU82968/98A AU8296898A (en) 1997-07-15 1998-07-08 Antacid and papain combination
CA002286357A CA2286357A1 (en) 1997-07-15 1998-07-08 Antacid and papain combination

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5254397P 1997-07-15 1997-07-15
US60/052,543 1997-07-15

Publications (1)

Publication Number Publication Date
WO1999003486A1 true WO1999003486A1 (en) 1999-01-28

Family

ID=21978305

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/014233 WO1999003486A1 (en) 1997-07-15 1998-07-08 Antacid and papain combination

Country Status (9)

Country Link
EP (1) EP1001796A1 (en)
JP (1) JP2002509539A (en)
AR (1) AR016514A1 (en)
AU (1) AU8296898A (en)
BR (1) BR9809419A (en)
CA (1) CA2286357A1 (en)
PE (1) PE102699A1 (en)
WO (1) WO1999003486A1 (en)
ZA (1) ZA986247B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056597A1 (en) * 2000-02-04 2001-08-09 Topic Empreendimentos E Participações S/C Ltda. Pharmaceutical carrier composition for papayne based products
WO2007010547A1 (en) * 2004-11-04 2007-01-25 Abhoy Sankar Arora A phyto-medicine and a process for the preparation thereof
WO2010055332A1 (en) * 2008-11-14 2010-05-20 Tanks And Vessels Industries Limited Improved proteinaceous digestates
IT201700090582A1 (en) * 2017-08-04 2019-02-04 Neilos S R L Composition for use in the prevention and / or treatment of gastric or gastroesophageal disorders.

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000083619A (en) * 1998-07-15 2000-03-28 Oju Seiyaku:Kk Health food and its preparation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHO, CHI HIN ET AL: "Papain reduces gastric acid secretion induced by histamine and other secretagogues in anesthetized rats", PROC. NATL. SCI. COUNC., REPUB. CHINA, PART B, 1984, 8, 177-81, XP002083166 *
RUHBACH W: "Klinische Erfahrungen mit Basofer", DTSCH MED J, NOV 5 1969, 20 (21) P660-2, GERMANY, WEST, XP002083165 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056597A1 (en) * 2000-02-04 2001-08-09 Topic Empreendimentos E Participações S/C Ltda. Pharmaceutical carrier composition for papayne based products
WO2007010547A1 (en) * 2004-11-04 2007-01-25 Abhoy Sankar Arora A phyto-medicine and a process for the preparation thereof
WO2010055332A1 (en) * 2008-11-14 2010-05-20 Tanks And Vessels Industries Limited Improved proteinaceous digestates
IT201700090582A1 (en) * 2017-08-04 2019-02-04 Neilos S R L Composition for use in the prevention and / or treatment of gastric or gastroesophageal disorders.
WO2019026047A1 (en) * 2017-08-04 2019-02-07 Neilos S.r.l. A composition for use in the prevention and/or treatment of gastric or gastroesophageal diseases

Also Published As

Publication number Publication date
AR016514A1 (en) 2001-07-25
PE102699A1 (en) 1999-11-05
JP2002509539A (en) 2002-03-26
ZA986247B (en) 1999-02-05
CA2286357A1 (en) 1999-01-28
EP1001796A1 (en) 2000-05-24
BR9809419A (en) 2000-06-13
AU8296898A (en) 1999-02-10

Similar Documents

Publication Publication Date Title
US4650669A (en) Method to make effervescent calcium tablets and calcium tablets produced thereby
CA2449521C (en) Pharmaceutical formulation, its use, and method for its manufacture
KR100238565B1 (en) Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress
US20100227006A1 (en) Powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis
AU1674692A (en) Chewable antacid compositions
US9186409B2 (en) Solid pharmaceutical composition for neutralizing stomach acid
Ericsson Monofluorophosphate physiology: general considerations
WO1999003486A1 (en) Antacid and papain combination
CA2085873A1 (en) Treatment
WO2002026213A1 (en) Pharmaceutical composition containing psyllium fiber and a lipase inhibitor
CA2171829A1 (en) Oral water soluble pharmaceutical compositions containing estrone derivative and calcium salt
RU2497527C2 (en) Pharmaceutical composition for treating disorders including gastrointestinal irritation
WO2023283141A1 (en) Alginate, polylysine, and seed preservative nutritional product and digestive aid
MXPA99008920A (en) Antacid and papain combination
WO2018117855A1 (en) Effervescent lozenge
WO2019026047A1 (en) A composition for use in the prevention and/or treatment of gastric or gastroesophageal diseases
US5661137A (en) Antacid pharmaceutical composition in the form of a suspension based on sucralfate gel
US4216207A (en) Method and composition for treatment of gastro-duodenal ulcers
WO2006100527A1 (en) Effervescent tablet containing sodium alendronate and related use and process
WO1996008238A1 (en) Use of paracellular absorption enhancers such as glucose for enhaincing the absorption of histamine h2-antagonists
WO1992015206A1 (en) A pulverous composition, a method for preparing it, and a method for improving the taste of the composition
EP1019066A1 (en) Methods and compositions for preventing and treating heartburn
KR960021033A (en) Pharmaceutical composition containing bamboo salt and antacid
Ushkalova Why are antacids prescribed in an hour. Features of the use of antacids: list and classification
Ushkalova What drugs are antacids? Antacids: principle of action, examples, indications for use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AU BA BB BG BR CA CN CZ EE GE HR HU ID IL IS JP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/008920

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2286357

Country of ref document: CA

Ref country code: CA

Ref document number: 2286357

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 82968/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 500213

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1998933290

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1998933290

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998933290

Country of ref document: EP